Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771340 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
A Phase 1 study of Uveal Melanoma and Choroid Neoplasm, sponsored by Iconic Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 8
- Study locations
NCT02771340 is a Phase 1 study of Uveal Melanoma and Choroid Neoplasm that has completed, run by Iconic Therapeutics. The registered enrollment target is 10 participants, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT02771340, a Phase 1 study of Uveal Melanoma and Choroid Neoplasm, has completed, sponsored by Iconic Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.
Conditions Studied
Interventions
- BIOLOGICAL ICON-1
Study Locations (8)
Michigan
- - Grand Rapids
- - Royal Oak
California
- - San Francisco
Colorado
- - Denver
Kansas
- - Leawood
Massachusetts
- - Boston
Oregon
- - Portland
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02771340
The ClinicalTrials.gov registry entry for NCT02771340 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is Iconic Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which ICON-1 is the first listed.
NCT02771340 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Michigan, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02771340 about?
NCT02771340 is a clinical study titled "Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma". The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the ...
What is the current status of trial NCT02771340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-05. Estimated completion is 2017-09.
What conditions does trial NCT02771340 study?
This clinical trial studies the following conditions: Uveal Melanoma, Choroid Neoplasm.
What interventions are being tested in trial NCT02771340?
The interventions under investigation include: ICON-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02771340?
This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02771340 being conducted?
This trial has 8 study locations across California, Colorado, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
RECRUITING · Phase 1
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.